These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26365492)

  • 21. Coronary artery disease potentiates response to dofetilide for rhythm control of atrial fibrillation.
    Manocha P; Bavikati V; Langberg J; Lloyd MS
    Pacing Clin Electrophysiol; 2012 Feb; 35(2):170-3. PubMed ID: 22017595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
    Abraham JM; Saliba WI; Vekstein C; Lawrence D; Bhargava M; Bassiouny M; Janiszewski D; Lindsay B; Militello M; Nissen SE; Poe S; Tanaka-Esposito C; Wolski K; Wilkoff BL
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):772-6. PubMed ID: 26063741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight.
    Waples JM; Moreb JS; Sugrue M; Belanger G; Kubilis P; Lynch JW; Gian V; Weeks F; Wingard J
    Bone Marrow Transplant; 1999 May; 23(9):867-73. PubMed ID: 10338040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation.
    Prystowsky EN; Freeland S; Branyas NA; Rardon DP; Fogel RI; Padanilam BJ; Rippy JS
    J Cardiovasc Electrophysiol; 2003 Dec; 14(12 Suppl):S287-90. PubMed ID: 15005216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
    Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
    Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial fluid resuscitation following adjusted body weight dosing is associated with improved mortality in obese patients with suspected septic shock.
    Taylor SP; Karvetski CH; Templin MA; Heffner AC; Taylor BT
    J Crit Care; 2018 Feb; 43():7-12. PubMed ID: 28823951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the dofetilide risk-management program.
    Allen LaPointe NM; Chen A; Hammill B; DeLong E; Kramer JM; Califf RM
    Am Heart J; 2003 Nov; 146(5):894-901. PubMed ID: 14597941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determining vancomycin clearance in an overweight and obese population.
    Leong JV; Boro MS; Winter M
    Am J Health Syst Pharm; 2011 Apr; 68(7):599-603. PubMed ID: 21411801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of machine learning in decision analysis for dose management for dofetilide.
    Levy AE; Biswas M; Weber R; Tarakji K; Chung M; Noseworthy PA; Newton-Cheh C; Rosenberg MA
    PLoS One; 2019; 14(12):e0227324. PubMed ID: 31891645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
    Wenzell CM; Gallagher EM; Earl M; Yeh JY; Kusick KN; Advani AS; Kalaycio ME; Mukherjee S; Tiu RV; Maciejewski JP; Sekeres MA
    Am J Hematol; 2013 Oct; 88(10):906-9. PubMed ID: 23828018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity and effectiveness of carboplatin in obese or overweight patients.
    Grueso Cuesta C; Poquet Jornet JE; Gasent Blesa JM; Valdivia Perez A; Carrera Hueso FJ; Moreno Royo L
    J Oncol Pharm Pract; 2019 Sep; 25(6):1328-1335. PubMed ID: 30086680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
    Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
    Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of fluid resuscitation on time to hemodynamic stability in obese patients with septic shock.
    Kiracofe-Hoyte BR; Doepker BA; Riha HM; Wilkinson R; Rozycki E; Adkins E; Lehman A; Van Berkel MA
    J Crit Care; 2021 Jun; 63():196-201. PubMed ID: 33012588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients.
    Spruill WJ; Wade WE; Huckaby WG; Leslie RB
    Am J Health Syst Pharm; 2001 Nov; 58(22):2143-6. PubMed ID: 11760916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation.
    Hicks C; Trickett A; Kwan YL; Ramanathan S
    Ann Hematol; 2012 Nov; 91(11):1795-801. PubMed ID: 22836946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight?
    Meyhoff CS; Lund J; Jenstrup MT; Claudius C; Sørensen AM; Viby-Mogensen J; Rasmussen LS
    Anesth Analg; 2009 Sep; 109(3):787-92. PubMed ID: 19690247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?
    Ali MY; Oyama Y; Monreal J; Winter JN; Tallman MS; Williams SF; Singhal S; Gordon LI; Mehta J
    Bone Marrow Transplant; 2003 May; 31(10):861-4. PubMed ID: 12748662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship among obesity, nutritional status, and mortality in the critically ill.
    Robinson MK; Mogensen KM; Casey JD; McKane CK; Moromizato T; Rawn JD; Christopher KB
    Crit Care Med; 2015 Jan; 43(1):87-100. PubMed ID: 25289931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.